LT3662910T - Trail geno indukcijai skirtas farmakoforas - Google Patents
Trail geno indukcijai skirtas farmakoforasInfo
- Publication number
- LT3662910T LT3662910T LTEP19218049.5T LT19218049T LT3662910T LT 3662910 T LT3662910 T LT 3662910T LT 19218049 T LT19218049 T LT 19218049T LT 3662910 T LT3662910 T LT 3662910T
- Authority
- LT
- Lithuania
- Prior art keywords
- pharmacophore
- gene induction
- trail gene
- trail
- induction
- Prior art date
Links
- 230000006698 induction Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461972689P | 2014-03-31 | 2014-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3662910T true LT3662910T (lt) | 2024-12-27 |
Family
ID=54241169
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP19218049.5T LT3662910T (lt) | 2014-03-31 | 2015-03-30 | Trail geno indukcijai skirtas farmakoforas |
| LTEP15772254.7T LT3125898T (lt) | 2014-03-31 | 2015-03-30 | Farmakoforas, skirtas trail indukcijai |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15772254.7T LT3125898T (lt) | 2014-03-31 | 2015-03-30 | Farmakoforas, skirtas trail indukcijai |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US10239877B2 (OSRAM) |
| EP (3) | EP3662910B1 (OSRAM) |
| JP (4) | JP6756435B2 (OSRAM) |
| KR (2) | KR102473930B1 (OSRAM) |
| CN (2) | CN106456643B (OSRAM) |
| AU (4) | AU2015241069B2 (OSRAM) |
| CA (2) | CA3158795A1 (OSRAM) |
| CY (1) | CY1123093T1 (OSRAM) |
| DK (2) | DK3125898T3 (OSRAM) |
| ES (2) | ES2779979T3 (OSRAM) |
| FI (1) | FI3662910T3 (OSRAM) |
| HR (2) | HRP20200478T1 (OSRAM) |
| HU (2) | HUE049013T2 (OSRAM) |
| LT (2) | LT3662910T (OSRAM) |
| PL (2) | PL3125898T3 (OSRAM) |
| PT (2) | PT3662910T (OSRAM) |
| RS (2) | RS60163B1 (OSRAM) |
| SI (2) | SI3125898T1 (OSRAM) |
| SM (2) | SMT202000219T1 (OSRAM) |
| WO (1) | WO2015153468A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2734568T3 (es) | 2013-03-13 | 2019-12-10 | Oncoceutics Inc | 7-Bencil-10-(2-metilbencil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3H)-ona para su uso en el tratamiento de cáncer |
| US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| CN106163524B (zh) * | 2013-11-15 | 2019-11-08 | 昂克希尔迪克斯有限公司 | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法 |
| EP3662910B1 (en) | 2014-03-31 | 2024-09-18 | The Scripps Research Institute | Pharmacophore for trail induction |
| JP6802172B2 (ja) * | 2015-01-30 | 2020-12-16 | オンコシューティクス インコーポレイテッドＯｎｃｏｃｅｕｔｉｃｓ，Ｉｎｃ． | ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| CN104860948B (zh) * | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
| BR112018015590A2 (pt) * | 2016-01-29 | 2019-10-01 | Oncoceutics Inc | modulação de receptor acoplado à proteína g (gpcr) por imipridonas |
| EP3496724B8 (en) | 2016-08-12 | 2021-11-17 | Madera Therapeutics, LLC | Protein kinase regulators |
| US10172862B2 (en) | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
| GB2596010B (en) * | 2019-02-11 | 2023-03-01 | Madera Therapeutics Llc | Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents |
| WO2020176654A1 (en) | 2019-02-27 | 2020-09-03 | Madera Therapeutics, LLC | Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents |
| WO2022029459A1 (en) | 2020-08-06 | 2022-02-10 | Eötvös Loránd Tudományegyetem | Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity |
| CN115448921B (zh) * | 2021-06-08 | 2023-08-01 | 四川大学 | 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途 |
| CN116751199B (zh) * | 2023-06-02 | 2025-03-18 | 中国科学院基础医学与肿瘤研究所(筹) | 一种线粒体蛋白酶靶向嵌合体、制备方法及用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE786028A (fr) * | 1971-07-08 | 1973-01-08 | Boehringer Sohn Ingelheim | 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer |
| DE2150062A1 (de) | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
| JPS5374893A (en) | 1976-12-15 | 1978-07-03 | Fujitsu Ltd | Driving method for semiconductor photosensitive device |
| JPS6132833U (ja) | 1984-07-31 | 1986-02-27 | 日信工業株式会社 | デイスクブレ−キ装置 |
| CA2485343A1 (en) * | 2002-05-23 | 2004-05-13 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| ES2665293T3 (es) * | 2008-06-09 | 2018-04-25 | Allergan, Inc. | Compuesto para tratar estados con mediación alfa-adrenérgica |
| EP2557923A4 (en) | 2010-04-16 | 2013-10-23 | Curis Inc | TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS |
| WO2012078448A1 (en) * | 2010-12-06 | 2012-06-14 | Schering Corporation | Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
| AU2012228334B2 (en) * | 2011-03-15 | 2017-03-23 | Chiesi Farmaceutici S.P.A. | Isoxazolidine derivatives |
| AU2012240246A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| RS65813B1 (sr) | 2011-04-29 | 2024-08-30 | Penn State Res Found | Indukcija malog molekula trail genom u normalnim i tumorskim ćelijama kao antikancerska terapija |
| WO2015073072A1 (en) * | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
| US9376437B2 (en) * | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| ES2734568T3 (es) * | 2013-03-13 | 2019-12-10 | Oncoceutics Inc | 7-Bencil-10-(2-metilbencil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3H)-ona para su uso en el tratamiento de cáncer |
| US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
| US9181237B2 (en) * | 2013-10-04 | 2015-11-10 | Mallinckrodt Llc | Substituted berbines and their synthesis |
| EP3662910B1 (en) | 2014-03-31 | 2024-09-18 | The Scripps Research Institute | Pharmacophore for trail induction |
-
2015
- 2015-03-30 EP EP19218049.5A patent/EP3662910B1/en active Active
- 2015-03-30 HR HRP20200478TT patent/HRP20200478T1/hr unknown
- 2015-03-30 ES ES15772254T patent/ES2779979T3/es active Active
- 2015-03-30 RS RS20200336A patent/RS60163B1/sr unknown
- 2015-03-30 AU AU2015241069A patent/AU2015241069B2/en active Active
- 2015-03-30 US US15/126,192 patent/US10239877B2/en active Active
- 2015-03-30 HU HUE15772254A patent/HUE049013T2/hu unknown
- 2015-03-30 CN CN201580021658.3A patent/CN106456643B/zh active Active
- 2015-03-30 RS RS20241340A patent/RS66254B1/sr unknown
- 2015-03-30 ES ES19218049T patent/ES2999685T3/es active Active
- 2015-03-30 LT LTEP19218049.5T patent/LT3662910T/lt unknown
- 2015-03-30 HR HRP20241680TT patent/HRP20241680T1/hr unknown
- 2015-03-30 CN CN202010184181.3A patent/CN111499636B/zh active Active
- 2015-03-30 KR KR1020167029994A patent/KR102473930B1/ko active Active
- 2015-03-30 PL PL15772254T patent/PL3125898T3/pl unknown
- 2015-03-30 CA CA3158795A patent/CA3158795A1/en active Pending
- 2015-03-30 SM SM20200219T patent/SMT202000219T1/it unknown
- 2015-03-30 EP EP24192819.1A patent/EP4470617A3/en active Pending
- 2015-03-30 EP EP15772254.7A patent/EP3125898B1/en active Active
- 2015-03-30 SM SM20240497T patent/SMT202400497T1/it unknown
- 2015-03-30 HU HUE19218049A patent/HUE069651T2/hu unknown
- 2015-03-30 CA CA2944452A patent/CA2944452C/en active Active
- 2015-03-30 DK DK15772254.7T patent/DK3125898T3/da active
- 2015-03-30 JP JP2016559887A patent/JP6756435B2/ja active Active
- 2015-03-30 LT LTEP15772254.7T patent/LT3125898T/lt unknown
- 2015-03-30 PT PT192180495T patent/PT3662910T/pt unknown
- 2015-03-30 PT PT157722547T patent/PT3125898T/pt unknown
- 2015-03-30 DK DK19218049.5T patent/DK3662910T3/da active
- 2015-03-30 KR KR1020227042050A patent/KR102611067B1/ko active Active
- 2015-03-30 PL PL19218049.5T patent/PL3662910T3/pl unknown
- 2015-03-30 WO PCT/US2015/023362 patent/WO2015153468A1/en not_active Ceased
- 2015-03-30 SI SI201531141T patent/SI3125898T1/sl unknown
- 2015-03-30 FI FIEP19218049.5T patent/FI3662910T3/fi active
- 2015-03-30 SI SI201532040T patent/SI3662910T1/sl unknown
-
2019
- 2019-03-20 US US16/359,633 patent/US10633385B2/en active Active
- 2019-09-10 JP JP2019164086A patent/JP6873201B2/ja active Active
-
2020
- 2020-03-20 CY CY20201100267T patent/CY1123093T1/el unknown
- 2020-04-14 US US16/848,032 patent/US20200283440A1/en not_active Abandoned
- 2020-12-11 AU AU2020286314A patent/AU2020286314A1/en not_active Abandoned
-
2021
- 2021-04-20 JP JP2021071035A patent/JP7186256B2/ja active Active
- 2021-07-12 US US17/372,894 patent/US11891392B2/en active Active
-
2022
- 2022-11-28 JP JP2022188821A patent/JP7688245B2/ja active Active
- 2022-12-08 AU AU2022283729A patent/AU2022283729A1/en not_active Abandoned
-
2023
- 2023-12-20 US US18/391,420 patent/US20240190877A1/en active Pending
-
2024
- 2024-07-19 AU AU2024204977A patent/AU2024204977A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3662910T (lt) | Trail geno indukcijai skirtas farmakoforas | |
| DK3102669T3 (da) | Forbedret bacillevært | |
| DK3233887T3 (da) | Immunmodulatorer | |
| PL3118311T3 (pl) | Antysensowny kwas nukleinowy | |
| HUE057846T2 (hu) | Permanens epigenetikus géncsendesítés | |
| HUE042335T2 (hu) | ROR-gamma dihidropirrolopiridin inhibitorai | |
| MA39481A (fr) | Thérapies ciblées | |
| DK3188836T3 (da) | Dna-syntese | |
| HUE054784T2 (hu) | 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók | |
| HUE054514T2 (hu) | Kemence | |
| HUE042087T2 (hu) | Inhalátor | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| FR3025617B1 (fr) | Architecture bi-voies | |
| IL249254A0 (en) | Gene expression system | |
| EP3125821C0 (en) | Insert for an inhaler | |
| IL257500A (en) | Altered cullin1 gene | |
| LT3628731T (lt) | Naujas antipresepsino antikūnas | |
| IL252086A0 (en) | Novel methods | |
| SG11201609108TA (en) | Antibody gene expression-secretion system | |
| EP2993051A4 (en) | PRINTER | |
| BR112017008675A2 (pt) | impressoras | |
| ES1135593Y (es) | Multibotella | |
| UA28521S (uk) | Наличка | |
| ES1122680Y (es) | Ladrillo caravista | |
| UA30864S (uk) | Інгалятор |